Zealand Pharma A/S (FRA:22Z)

Market Cap	3.96B
Revenue (ttm)	1.23B
Net Income (ttm)	876.08M
Shares Out	n/a
EPS (ttm)	12.27
PE Ratio	4.52
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	79
Average Volume	163
Open	64.02
Previous Close	65.40
Day's Range	64.02 - 64.02
52-Week Range	41.45 - 106.20
Beta	n/a
RSI	38.18
Earnings Date	Feb 19, 2026

About Zealand Pharma

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 335
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 22Z

Financial Performance

In 2024, Zealand Pharma's revenue was 62.69 million, a decrease of -81.71% compared to the previous year's 342.79 million. Losses were -1.08 billion, 53.3% more than in 2023.

Financial numbers in DKK